AI systems now integrate genomics, epigenomics, proteomics, microbiome signatures, and digital biomarkers to detect early deviations from healthy aging patterns before clinical disease appears. These predictive models enable personalized interventions targeting nutrition, metabolic optimization, sleep regulation, and stress management based on individual biological aging profiles rather than chronological age alone. This represents a fundamental shift in healthcare architecture from reactive treatment models to continuously monitored, adaptive prevention systems. The convergence of AI with longevity medicine addresses a critical gap in current healthcare—the inability to intervene before pathological processes become clinically apparent. While promising, this approach faces substantial hurdles including data fragmentation across biomarker ecosystems, potential overmedicalization of aging, and inequitable access to advanced preventive technologies. The success of AI-enhanced longevity medicine hinges on developing interoperable data infrastructures and federated learning systems that can bridge siloed biological datasets. More critically, ensuring these powerful predictive capabilities remain clinically relevant and ethically grounded will determine whether this technological evolution truly democratizes healthspan extension or exacerbates existing healthcare disparities.